Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $77.00 price target on the biotechnology company’s stock.

CAPR has been the topic of several other research reports. Oppenheimer reiterated an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Maxim Group raised their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 target price on the stock. Finally, Cantor Fitzgerald lifted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Stock Performance

CAPR traded down $0.07 on Thursday, reaching $18.42. The company had a trading volume of 621,138 shares, compared to its average volume of 1,146,085. The stock has a market cap of $836.45 million, a P/E ratio of -17.44 and a beta of 4.00. Capricor Therapeutics has a fifty-two week low of $2.87 and a fifty-two week high of $23.40. The company’s fifty day moving average is $14.63 and its 200 day moving average is $8.29.

Insider Activity

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the stock in a transaction dated Friday, September 20th. The stock was bought at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the purchase, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This represents a 65.21 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asset Management L.P. acquired a new position in Capricor Therapeutics during the 3rd quarter worth approximately $3,806,000. PFM Health Sciences LP acquired a new position in shares of Capricor Therapeutics during the third quarter worth approximately $2,324,000. Fred Alger Management LLC bought a new position in shares of Capricor Therapeutics in the 3rd quarter worth $399,000. BNP Paribas Financial Markets grew its position in Capricor Therapeutics by 868.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 15,872 shares during the period. Finally, FMR LLC bought a new stake in Capricor Therapeutics during the 3rd quarter valued at $370,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.